Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
8.91
+0.14 (1.60%)
At close: Dec 24, 2025, 1:00 PM EST
8.96
+0.05 (0.56%)
After-hours: Dec 24, 2025, 5:00 PM EST
Ginkgo Bioworks Holdings Revenue
Ginkgo Bioworks Holdings had revenue of $38.84M in the quarter ending September 30, 2025, a decrease of -56.39%. This brings the company's revenue in the last twelve months to $180.61M, down -17.13% year-over-year. In the year 2024, Ginkgo Bioworks Holdings had annual revenue of $227.04M, down -9.71%.
Revenue (ttm)
$180.61M
Revenue Growth
-17.13%
P/S Ratio
2.70
Revenue / Employee
$216,554
Employees
834
Market Cap
506.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 227.04M | -24.41M | -9.71% |
| Dec 31, 2023 | 251.46M | -226.25M | -47.36% |
| Dec 31, 2022 | 477.71M | 163.87M | 52.21% |
| Dec 31, 2021 | 313.84M | 237.18M | 309.40% |
| Dec 31, 2020 | 76.66M | 22.47M | 41.48% |
| Dec 31, 2019 | 54.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DNA News
- 2 days ago - Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach - PRNewsWire
- 7 days ago - Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment - PRNewsWire
- 13 days ago - ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies - GlobeNewsWire
- 15 days ago - Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety - PRNewsWire
- 19 days ago - Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC - PRNewsWire
- 21 days ago - STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy - PRNewsWire
- 5 weeks ago - Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health - PRNewsWire
- 6 weeks ago - Ginkgo Bioworks: Not There Yet - Seeking Alpha